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a 3-Year-old Girl with Recurrent 
Infections and autoimmunity due to 
a STAT1 Gain-of-Function Mutation: 
the expanding Clinical presentation 
of primary Immunodeficiencies
Juan Carlos Aldave Becerra* and Enrique Cachay Rojas
Allergy and Immunology Division, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru
We report a 3-year-old Peruvian girl, born to non-consanguineous parents. At the age 
of 8 months, she had a severe pneumonia complicated with empyema that required 
thoracic drainage and mechanical ventilation. Although no microorganisms were iso-
lated, the patient recovered with broad-spectrum antibiotics. Since that date, she has 
presented multiple episodes of pneumonia and recurrent episodes of bronchospasm. 
At 1 year 5 months of age, the patient began with recurrent episodes of oropharyngeal, 
vaginal, and skin candidiasis, which improved transiently after using oral azole drugs. 
At 2.5  years of age, she was admitted with lupus-like syndrome, including serositis, 
hemolytic anemia, thrombocytopenia, and positive antinuclear (1:80) and dsDNA (1:10) 
autoantibodies. Available immunologic testing was not contributory. Imaging studies 
revealed bilateral ethmoidal sinusitis and mild hepatomegaly. Bone marrow analysis 
did not showed evidence of leukemia or myelodysplasia, while renal biopsy concluded 
mild mesangial proliferation. Genetic studies revealed a pathogenic heterozygous signal 
transducer and activator of transcription 1 gain-of-function mutation (WT/P293L). The 
clinical status and lung function of the patient has worsened progressively. She has 
not achieved an optimal response to therapy, including high-dose intravenous immuno-
globulin, GM-CSF, prophylactic antibiotics and antifungal drugs, so we plan to perform 
hematopoietic stem cell transplantation.
Keywords: signal transducer and activator of transcription 1, gain-of-function mutation, immunodeficiency, 
autoimmunity, hematopoietic stem cell transplantation
INtRoDUCtIoN aND BaCKGRoUND
We report the case of a 3-year-old Peruvian girl who displayed recurrent infections by Candida 
albicans and pyogenic bacteria, as well as clinical features of autoimmunity. Our patient was born to 
non-consanguineous Mestizo parents. There was no family history suggestive of primary immuno-
deficiencies (PIDs). Her parents and an older brother were apparently healthy. The patient had no 
adverse reaction to the BCG vaccine.
We evaluated the patient for the first time when she was 2.5 years old. She had been admitted to our hos-
pital with a diagnosis of lupus-like syndrome, including serositis (pleural and pericardial effusion), hemolytic 
2Aldave Becerra and Cachay Rojas A 3-Year-Old Girl with Recurrent Infections and Autoimmunity
Frontiers in Pediatrics | www.frontiersin.org March 2017 | Volume 5 | Article 55
anemia, autoimmune thrombocytopenia, and proteinuria. Laboratory 
testing revealed the presence of positive antinuclear (1:80) and dsDNA 
(1:10) autoantibodies. Imaging studies reported bilateral ethmoidal 
sinusitis and mild hepatomegaly. Bone marrow smear and biopsy did 
not show evidence of leukemia or myelodysplasia, while renal biopsy 
concluded the existence of mild mesangial proliferation. At that time, 
clinical disease partially improved with systemic corticosteroids.
After looking at her past clinical history, we realized that the patient 
also displayed increased susceptibility to infections. At the age of 
8 months, she had a severe pneumonia complicated with empyema 
that required thoracic drainage and mechanical ventilation. Although 
no microorganisms were isolated, the patient recovered with broad-
spectrum antibiotics. From then, she had multiple episodes of pneu-
monia and recurrent bronchospasm that required long-term treatment 
with inhaled corticosteroids. Furthermore, since 1 year 5 months of 
age, the patient suffered from recurrent oropharyngeal, vaginal, and 
skin infections by C. albicans, which worsened while receiving corti-
costeroids for the autoimmune phenomena and improved transiently 
after using oral fluconazole. Chronic diarrhea and failure to thrive 
were prominent clinical features from 2 years of age.
Upon suspicion of PID, available immunologic work up was 
requested. Serum immunoglobulins were within normal levels, as well 
as T, B, and NK lymphocyte counts. Serum complement proteins C3, 
C4, C1, C1q, and C2 were not decreased.
Advanced immunologic testing, including lymphoprolifera-
tion studies, assessment of T helper subpopulations, and innate 
immune functional evaluation were not available in Peru at that 
time. Therefore, we quickly decided to search for international 
collaboration. Two months later, genetic studies using Sanger 
sequencing revealed a heterozygous gain-of-function (GOF) muta-
tion (P293L) located in the coiled-coil domain of the transcription 
factor signal transducer and activator of transcription 1 (STAT1).
Despite therapy, the clinical status and lung function of the 
patient has worsened progressively over the following months. 
Computer tomography of the chest at 3 years of age revealed dif-
fuse chronic inflammatory lung disease with bilateral bronchiec-
tasis. The patient has not achieved successful response to several 
treatments, including prophylactic cotrimoxazole, azithromycin 
and fluconazole, high-dose (1 g/kg monthly) intravenous immu-
noglobulin, and granulocyte colony-stimulating factor (G-CSF). 
Therefore, we consider her a candidate to receive hematopoietic 
stem cell transplantation (HSCT).
However, there are several limitations to perform HSCT in 
developing countries like Peru. These limitations include (a) 
lack of bone marrow national registry to find HLA-matched 
unrelated donors, (b) difficulty to carry out haploidentical HSCT, 
and (c) scarce human, technologic, administrative, and economic 
resources. Our reported patient does not have a HLA-matched 
related donor. As a consequence, 3  years after performing the 
definitive genetic diagnosis, HSCT has not been done yet. It is 
important to consider that efficacy of HCST to treat severe disease 
due to STAT1 GOF mutations has not been fully defined.
DIsCUssIoN
Signal transducer and activator of transcription 1 GOF mutations 
reduce the dephosphorylation of activated STAT1 protein, leading 
to accumulation of phosphorylated STAT1 in the nucleus (1, 2). 
Persistently activated STAT1 may shift the immune response toward 
STAT1-dependent interleukin-17 inhibitors and away from STAT3-
mediated TH17 cell generation (3, 4). GOF mutations affecting STAT1 
lead to defective TH17 cell development, characterized by reduced 
production of IL-17 and IL-22; these cytokines are crucial for antifun-
gal and antibacterial defense in skin and mucosa (2, 5–8). An increased 
signaling of interferons and IL-27 through STAT1 cause an elevated 
risk of autoimmune phenomena (2).
Patients with GOF STAT1 mutations usually present with auto-
somal dominant chronic mucocutaneous candidiasis and infections 
by extracellular bacteria, mainly Staphylococcus aureus (2). Other 
prominent clinical manifestations include cutaneous dermatophytosis, 
cerebral aneurisms, carcinomas, mycobacterial disease, and autoim-
mune phenomena such as hypothyroidism, autoimmune hepatitis and 
lupus-like syndrome (3, 6, 9). GOF STAT1 mutations can also underlie 
disseminated coccidioidomycosis and histoplasmosis (10), recalcitrant 
cutaneous fusariosis (11), susceptibility to viral infections (12, 13), 
IPEX-like syndrome (14), severe combined immunodeficiency (15), 
and common variable immunodeficiency (16).
Current therapy for patients with GOF STAT1 mutations is 
based on the use of long-term antifungal and antibacterial drugs (2). 
Some affected individuals have been treated with the JAK1/JAK2 
inhibitor ruxolitinib (17, 18), G-CSF, GM-CSF, and intravenous 
immunoglobulin (9), with inconsistent outcomes. HSCT should 
be considered as a treatment option for patients with severe clinical 
course (9). Availability of HSCT might be a critical determinant of 
survival in these patients.
CoNCLUDING ReMaRKs
We report a 3-year-old Peruvian girl with a GOF STAT1 mutation who 
displayed infections by C. albicans and pyogenic bacteria, as well as 
clinical features of autoimmunity. The clinical presentation of GOF 
STAT1 mutations is highly variable. Severe life-threatening disease 
might require HSCT, a complex therapy that usually is not promptly 
available in developing countries.
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